NEW YORK (GenomeWeb) – Investment bank Barclays on Tuesday initiated coverage of the life science tools and diagnostics industry with the start of coverage on five firms and the upgrade of another company in the molecular diagnostics and omics tools space.

In a report, analyst Jack Meehan initiated coverage of Thermo Fisher Scientific and Myriad Genetics with Overweight ratings. He also gave Equal Weight ratings to Illumina and Agilent Technologies, and an Underweight rating to Hologic, while he upgraded Qiagen to an Overweight rating.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.